06:01 EST Day One Biopharmaceuticals (DAWN) to acquire Mersana Therapeutics (MRSN) for up to $285M
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DAWN:
- Day One Biopharmaceuticals price target raised to $27 from $26 at JPMorgan
- Day One Biopharma’s Positive Q3 Earnings Call
- Strong Buy Recommendation for Day One Biopharmaceuticals Driven by Robust Financial Performance and Promising Drug Efficacy
- Positive Outlook for Day One Biopharmaceuticals: Strong Q3 Performance and Upgraded Guidance Justify Buy Rating
- Day One Biopharmaceuticals price target raised to $26 from $25 at Piper Sandler